82 related articles for article (PubMed ID: 31609221)
1. p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Wei W; Ji M; Wu CP; Yang X
Lancet; 2019 Oct; 394(10206):1321-1322. PubMed ID: 31609221
[No Abstract] [Full Text] [Related]
2. p16 status and choice of chemotherapy in the KEYNOTE-040 study.
Bins S; Mathijssen RHJ
Lancet; 2019 Oct; 394(10206):1322-1323. PubMed ID: 31609222
[No Abstract] [Full Text] [Related]
3. p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply.
Cohen EEW; Soulières D; Swaby RF; Harrington KJ
Lancet; 2019 Oct; 394(10206):1323. PubMed ID: 31609223
[No Abstract] [Full Text] [Related]
4. [Pembrolizumab is more effective and better tolerable than methotrexate, docetaxel, or cetuximab in recurrent or metastatic HNSCC (KEYNOTE-040)].
Hermann RM; Christiansen H
Strahlenther Onkol; 2019 Sep; 195(9):851-854. PubMed ID: 31250051
[No Abstract] [Full Text] [Related]
5. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study.
Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F
Oncology; 2013; 84(4):251-4. PubMed ID: 23428719
[TBL] [Abstract][Full Text] [Related]
6. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
[TBL] [Abstract][Full Text] [Related]
7. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U
Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686
[TBL] [Abstract][Full Text] [Related]
8. Keynote 48: Is it really for everyone?
Schoenfeld JD; Fell G; Haddad RI; Trippa L
Oral Oncol; 2020 Jun; 105():104762. PubMed ID: 32381470
[No Abstract] [Full Text] [Related]
9. Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck.
Li JZ; Zheng JW; Zhang ZY
Shanghai Kou Qiang Yi Xue; 2008 Feb; 17(1):1-5. PubMed ID: 18360658
[TBL] [Abstract][Full Text] [Related]
10. Further clinical interpretation and implications of KEYNOTE-048 findings.
McCaw ZR; Ludmir EB; Kim DH; Wei LJ
Lancet; 2020 Aug; 396(10248):378-379. PubMed ID: 32771102
[No Abstract] [Full Text] [Related]
11. Further clinical interpretation and implications of KEYNOTE-048 findings.
Szturz P; Vermorken JB
Lancet; 2020 Aug; 396(10248):379. PubMed ID: 32771103
[No Abstract] [Full Text] [Related]
12. Further clinical interpretation and implications of KEYNOTE-048 findings.
Revannasiddaiah S; Devadas SK; Maka VV; Kilara N
Lancet; 2020 Aug; 396(10248):378. PubMed ID: 32771101
[No Abstract] [Full Text] [Related]
13. Reply to "Keynote 48: Is it really for everyone?".
Burtness B; Ge J
Oral Oncol; 2021 Jan; 112():104983. PubMed ID: 33032941
[No Abstract] [Full Text] [Related]
14. Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
Trieu V; Pinto H; Riess JW; Lira R; Luciano R; Coty J; Boothroyd D; Colevas AD
Oncologist; 2018 Jul; 23(7):764-e86. PubMed ID: 29540603
[TBL] [Abstract][Full Text] [Related]
15. PD-1 antibodies in head-and-neck cancer.
Wollenberg B
Lancet; 2019 Jan; 393(10167):108-109. PubMed ID: 30509741
[No Abstract] [Full Text] [Related]
16. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
17. Cetuximab in the treatment of squamous cell carcinoma of the head and neck.
Specenier P; Vermorken JB
Expert Rev Anticancer Ther; 2011 Apr; 11(4):511-24. PubMed ID: 21504318
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in head and neck cancer: aiming at EXTREME precision.
Szturz P; Vermorken JB
BMC Med; 2017 Jun; 15(1):110. PubMed ID: 28571578
[TBL] [Abstract][Full Text] [Related]
19. Afatinib in squamous cell carcinoma of the head and neck.
Specenier P; Vermorken J
Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335
[TBL] [Abstract][Full Text] [Related]
20. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
